Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 7 records in total 7
    records per page




    Analysis of Clinical Imaging Characteristics of Patients with 2019-nCoV

    Authors: Hao Jiang; WEI GUO; Huijie Jiang; Ruoshui Zheng; Ziao Wang; Ru Yi; Baomin Su; Li Sun

    doi:10.21203/rs.3.rs-44768/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: This article retrospectively analyzed the clinical characteristics and CT characteristics of chest CT of 10 patients with coronavirus disease MESHD 2019 (COVID-19) diagnosed in Heilongjiang Province. Methods: A retrospective analysis of 10 COVID-19 patients confirmed by designated hospitals in Heilongjiang Province. Results: The clinical manifestations were mainly fever HP fever MESHD (80%) and cough HP cough MESHD (50%). Laboratory tests showed elevated C-reactive protein (70%) and serum SERO amyloid A (80%). CT mainly manifests as ground-glass opacity (100%) in the lung, more than two lung lobes (90%), and the lesions are mostly located in the right upper lobe (80%), and lobular septum thickening (60%) is common.Conclusions: In this group of patients with COVID-19, the typical CT manifestations are double lung sheet ground-glass opacity, which are mainly distributed in the subpleural area, and the range of involvement is more than or equal to two lung lobes, “paving stones” changes; pulmonary lesions were absorbed and fibrous cord foci were formed during the transition period. It is worth noting that hilum, mediastinal lymphadenopathy HP mediastinal lymphadenopathy MESHD, and pleural effusion HP pleural effusion MESHD are less common. During the study period, follow-up imaging performed by some patients showed mild / moderate disease progression and gradually dissipating.

    Clinical Characteristics of COVID-19 and the Value of Mulbsta Scoring System in Prognosis Evaluation

    Authors: Chao Wang; Zhixiu Luo; Junyi Wu; Jie Zhou; Yahang Lin; Guilin Yan; Manman Yan; Xi Wang; Hanhua Yu; Xiaoyun Zeng

    doi:10.21203/rs.3.rs-35521/v1 Date: 2020-06-14 Source: ResearchSquare

    BackgroundCOVID-19, a worldwideinfectious disease MESHD, has killed more than 420000 people, whichis extremely harmful.MethodsIn this single-center retrospective study, we included the novel coronavirus pneumonia MESHD pneumonia HP confirmed in our hospital. This study collected the basic information andclinical examination features.ResultsThe enrolled 704 patients were affirmed infected with 2019-nCoV by the test of throat swabs. There are 334 men and 369 women, and gender TRANS, age TRANS, combined with basic diseasesare distinct in diverse disease classification (p<0.05). From the symptom analysis, the proportion of fever HP fever MESHD over 38 degrees, dyspnea HP dyspnea MESHD, fatigue HP fatigue MESHD, poor appetite HP and other symptoms is diverse in different types of diseases (p<0.05). As the severity of the disease increases, the median lymphocyte count decreases, C-reactive protein increase, erythrocyte sedimentation rateincrease, albumin decrease, pleural effusion HP pleural effusion MESHD increase, D-Dimer and NT-proBNP increase significantly (p<0.05).As the disease severity increases, the average value of MuLBSTA score obviously ascend (p<0.05), MuLBSTA scoring system predicts novel coronavirus pneumonia MESHD pneumonia HP patients' prognosis is still insufficient, and may require additional indicators including anorexia HP anorexia MESHD, fatigue HP fatigue MESHD, C reactive protein, etc (p<0.05).ConclusionThe MuLBSTA evaluation system has certain value for the evaluation of the disease, but it needs to be improved.

    Comparison of initial HRCT features of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia HP pneumonia MESHD, the pneumonias HP pneumonias MESHD were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias HP pneumonias MESHD included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias HP pneumonias MESHD were analyzed and compared.Results: Fever HP Fever MESHD and cough HP cough MESHD were the most common clinical symptoms of the four viral pneumonias HP pneumonias MESHD. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue HP fatigue MESHD, sore throat, expectorant and chest tightness HP chest tightness MESHD (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency HP immunodeficiency MESHD syndrome ( AIDS MESHD) and leukopenia HP leukopenia MESHD were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias HP pneumonias MESHD showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias HP pneumonias MESHD, COVID-19 pneumonia HP pneumonia MESHD was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP pleural thickening MESHD and pleural effusion HP pleural effusion MESHD were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    The first 2019-nCoV infection case report from Iran

    Authors: Maryam Mansoori; Somayeh Vafaei; Zahra Madjd; Masoume Mesgarian

    doi:10.21203/rs.3.rs-26452/v1 Date: 2020-05-01 Source: ResearchSquare

    Background: The total mortality rate of COVID-19 is estimated almost at 2 % based on a wide range of publications. To avoid negative global impact of this new emergency, the entailment of control measures for prevention is highly recommended. Unfortunately, Iran has been the manifestation of attention as one of the countries is struggling with this pandemic. Here we intend to report a unique case of 2019-nCoV infected patient with underlying diseases MESHD and one of the rare pulmonary manifestations of 2019-nCoV infection MESHD ( pleural effusion HP pleural effusion MESHD) who has recovered and discharged. Case presentation: The current case report from Iran showed a positive COVID-19 case accompanied by pleural effusion HP pleural effusion MESHD and severe pneumonia HP pneumonia MESHD and even underlying diseases. She received twelve days of treatment and recovered with good oxygen saturation and without associated factors including fever HP fever MESHD and cough HP cough MESHD. In this report, presentations, diagnoses and management of novel 2019 coronavirus patient has been described in details. Conclusions: The pleural effusion HP pleural effusion MESHD in 2019-nCoV is not a dominant feature and can be considered as one of the diagnostic features in the disease. Even with underlying diseases, 2019-nCoV symptoms are not supposed to be severed. 

    In-flight Transmission TRANS Cluster of COVID-19: A Retrospective Case Series

    Authors: Naibin Yang; Yuefei Shen; Chunwei Shi; Ada Hoi Yan Ma; Xie Zhang; Xiaomin Jian; Liping Wang; Jiejun Shi; Chunyang Wu; Guoxiang Li; Yuan Fu; Keyin Wang; Mingqin Lu; Guoqing Qian

    doi:10.1101/2020.03.28.20040097 Date: 2020-03-30 Source: medRxiv

    Objectives: No data were available about in-flight transmission TRANS of SARS-CoV-2. Here, we report an in-flight transmission TRANS cluster of COVID-19 and describe the clinical characteristics of these patients. Methods: After a flight, laboratory-confirmed COVID-19 was reported in 12 patients. Ten patients were admitted to the designated hospital. Data were collected from 25th January to 28th February 2020. Clinical information was retrospectively collected. Results: All patients are passengers without flight attendants. The median age TRANS was 33 years, and 70% were females TRANS. None was admitted to intensive care unit, and no patients succumbed through 28th February. The median incubation period TRANS was 3.0 days and from illness onset to hospital admission was 2 days. The most common symptom was fever HP fever MESHD. Two patients were asymptomatic TRANS and negative for chest CT scan throughout the disease course. On admission, initial RT-PCR were positive in 9 patients, however initial chest CT were positive in only half patients. The median lung total severity score of chest CT was 6. Notably, Crazy-Paving pattern, pleural effusion HP pleural effusion MESHD, and ground-glass nodules were also seen. Conclusion: It is potential for COVID-19 transmission TRANS by airplane, but the symptoms are mild. Passengers and attendants must be protected during the flight.

    Early CT manifestations and short-term evolution of coronavirus disease-2019

    Authors: Wei Wei; Wen Xiao Hu; Fu Wei Lv

    doi:10.21203/rs.3.rs-19012/v1 Date: 2020-03-24 Source: ResearchSquare

    Objectives: This study explored the features of coronavirus disease-2019 (COVID-19) with the aim of improving clinical diagnosis.Methods: We retrospectively analyzed the clinical and CT data of 85 patients with COVID-19 who were diagnosed between January 20, 2020 and February 20, 2020. The imaging findings, clinical and laboratory data were evaluated.Results: Of the 85 patients, five had mild symptoms, 60 had moderate symptoms, and 20 had severe symptoms. Sixty-nine patients had direct or indirect contact history, while 16 patients (19%) had no obvious epidemiological history. Eighty-five patients had prominent respiratory symptoms, while 70 patients (82%) had moderate to low fever MESHD fever HP. There were no obvious lung abnormalities MESHD in CT images of patients with mild symptoms. Common chest CT manifestations in patients with moderate or severe symptoms were ground glass opacity (GGO) (16%); GGO combined with grid (39%) or consolidation (32%); and air bronchogram sign (13%). In these patients, lesions were mostly distributed in the lower lobes of the lungs, and most were located in the periphery; pleural effusion HP pleural effusion MESHD was rare. Within 3 days after onset, GGO (23%) and GGO combined with grid (45%) were the most common manifestations in CT images; GGO combined with grid (35%) and/or consolidation (41%) were the main manifestations in CT images at 5–10 days after onset.Conclusions: Common CT manifestations of COVID-19 were GGO alone and GGO combined with grid and/or consolidation. Short-term increases in ranges of lesions or consolidation areas may indicate disease aggravation.

    Clinical characterization and chest CT findings in laboratory-confirmed COVID-19: a systematic review and meta-analysis

    Authors: Golnaz Vaseghi; Marjan Mansourian; Raheleh Karimi; Kiyan Heshmat-Ghahdarijani; Sadegh Baradaran Mahdavi; Amirhossein Pezeshki; Behrooz Ataei; Alireza Zandifar; Omid Shafaat; Shaghayegh Haghjoo Javanmard

    doi:10.1101/2020.03.05.20031518 Date: 2020-03-08 Source: medRxiv

    Background: Imagery techniques have been used as essential parts of diagnostic workup for patients suspected for 2019-nCoV infection MESHD, Multiple studies have reported the features of chest computed tomography (CT) scans among a number of 2019-nCoV patients. Method: Study Identification was carried out in databases (PubMed, Embase and Cochrane Library) to identify published studies examining the diagnosis, the 2019 novel coronavirus (2019-nCoV). Heterogeneity among reported prevalence SERO was assessed by computing p-values of Cochrane Q-test and I2-statics. The pooled prevalence SERO of treatment failure was carried out with a fixed effects meta-analysis model, generating the pooled 95% confidence interval. A random-effect model was used to pool the results since this model could incorporate the heterogeneity of the studies and therefore proved a more generalized result. Results: According to the combined results of meta-analysis, the total 55% of corona patients were males TRANS. The mean age TRANS of the patients was 41.31 (34.14, 48.47). Two prevalent clinical symptoms between patients were fever HP fever MESHD, cough HP cough MESHD with prevalence SERO of 85%, and 62%, respectively. Either Ground Glass Opacity GGO or consolidation was seen in 86% but 14% had NO GGO or consolidation. The other rare CT symptoms were pericardial effusion HP, and pleural effusion HP pleural effusion MESHD with 4, 5, 7% prevalence SERO, respectively. The most prevalent event was Either GGO or consolidation in 85% of patients. Conclusion: The most CT-scan abnormality is Either Ground Glass Opacity GGO or consolidation however in few patients none of them might be observed, so trusting in just CT findings will lead to miss some patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.